PA 452

Key Product Details

Product Description

PA 452 is an RXR antagonist (pA₂ = 7.11). Triggers dissociation of RXR tetramers. Attenuates cell proliferation and induces apoptosis in MCF-7 breast cancer cells.

Product Specifications for PA 452

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for PA 452

The following data is based on the product molecular weight 439.59.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.27 mL	11.37 mL	22.75 mL
5 mM	0.45 mL	2.27 mL	4.55 mL
10 mM	0.23 mL	1.14 mL	2.27 mL
50 mM	0.05 mL	0.23 mL	0.45 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 8 publications citing the usage of this product.

• Takahashi Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions. J.Med.Chem. 2002 PMID: 12139443
• Nakayama Discovery of a potent retinoid X receptor antagonist structurally closely related to RXR agonist NEt-3IBIB. J.Med.Chem.Lett 2011 PMID: 24900278
• Yasmin Inhibition of mammary carcinoma cell growth by RXR is mediated by the receptor's oligomeric switch. J.Mol.Biol. 2010 PMID: 20188110

Product Documents for PA 452